AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04526795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04526795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcrisantaspase
Description: Given IV
Study NCT05175755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients
Description: The procedure involves taking a total of 12 ml of blood.
Study NCT05618795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: minimal gap arthoplasty v/s aggressive gap arthoplasty
Description: Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
Study NCT05618795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: minimal gap arthoplasty v/s aggressive gap arthoplasty
Description: Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
Study NCT04847869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellex Integre NIR laser
Description: The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
Study NCT05279170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children
Description: Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs
Study NCT06285877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy sessions
Description: Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
Study NCT06285877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy sessions plus Nintendo Switch
Description: Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
Study NCT05646667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interscalene with Erector spinae plane block group
Description: patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
Study NCT05646667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interscalene group
Description: patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
Study NCT06378554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT05566223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
Study NCT05566223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Study NCT05566223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CISH Inactivated TIL
Description: Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
Study NCT05566223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
Study NCT05566223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
Study NCT05178160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP Standard Protocol
Description: All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
Study NCT05178160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP Standard Protocol
Description: All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
Study NCT06217367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Diphenhydramine
Description: Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Study NCT06217367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine
Description: Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Study NCT06217367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Desloratadine
Description: Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Study NCT06217367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Study NCT04962425 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
Study NCT06332885 — intervention group
Intervention type: DEVICE
Intervention: Zephyr Endobronchial Valve
Description: Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
Study NCT06158698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
Study NCT06158698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
Study NCT06658197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
Study NCT06658197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
Study NCT06664918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral food challenge (OFC)
Description: oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)
Study NCT06664918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral food challenge (OFC)
Description: oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
Study NCT06602232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 will be administered via IV infusion.
Study NCT06602466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste
Description: 0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
Study NCT06602466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: Commercial toothpaste containing 1450 ppm fluoride.
Study NCT05560854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered prolonged exposure
Description: Internet delivered prolonged exposure for ten weeks with therapist support.
Study NCT06668376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leg Sleeve
Description: Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
Study NCT06668376 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
Study NCT06252779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma therapy equipment
Description: The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.
Study NCT06252779 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fake therapeutic device
Description: False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
Study NCT06054906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab+metronomic PLOF
Description: Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles
Study NCT06624085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
Study NCT06624085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Study NCT06624085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV obinutuzumab pretreatment
Study NCT06624085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
Study NCT06624085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
Study NCT06684119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography positive end-expiratory pressure titration
Description: A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
Study NCT06221241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000623
Description: tablets for oral administration.
Study NCT06695195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: 25 mg capsule twice daily
Study NCT06221241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: capsules for oral administration.
Study NCT06221241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin
Study NCT06221241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin
Study NCT06221241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin
Study NCT06695195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg capsule twice daily
Study NCT06723678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two distally inclined 45-degree angle posterior implants
Description: During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.
Study NCT06723678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two distally inclined 30-degree angle posterior implants
Description: During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsy
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsy
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06733350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06733350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo standard AS
Study NCT06733350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo standard AS
Study NCT06733350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06733350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04955314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PA vertebral mobilization
Description: A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
Study NCT04981808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring of CGM and insulin pen data
Study NCT04797702 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Glumetinib combined with Toripalimab
Description: Ib：All enrolled subjects received Glumetinib combined with Toripalimab on a 21-day cycle, starting with 200mg/ day continuous Glumetinib and 240mg/ 3 weeks Toripalimab.~II：The SMC will determine the dose group for the Phase II study based on the safety and initial efficacy data of the Phase Ib subjects. Approximately 62 evaluable subjects will be enrolled in the study to receive the recommended dose of Glumetinib once daily and continuous treatment with Toripalimab 240mg every 3 weeks.
Study NCT06733350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Testosterone
Description: Given via injection, gel, lotion, or transdermal patch
Study NCT06733064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin D3
Description: Supplementation of vitamin d3 at a dose of 4000 iu / day
Study NCT06733064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegetable oil as a placebo
Study NCT06477562 — intervention group
Intervention type: OTHER
Intervention: Endoscopy
Description: surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
Study NCT03037814 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compomer
Description: Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
Study NCT03037814 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RMGIC
Description: Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
Study NCT06733103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Cognitive Behavioural Therapy
Description: This is the only intervention in this clinical (feasibility) study
Study NCT06732076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based education
Description: web based education
Study NCT03037814 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Giomer
Description: Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
Study NCT06732362 — intervention group
Intervention type: OTHER
Intervention: Different DPN ratings
Description: According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
Study NCT06732648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS8179 injection
Description: HRS8179 injection; high dose
Study NCT06732648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS8179 blank preparation.
Description: HRS8179 blank preparation.
Study NCT06732219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional Communication Training (FCT) focuses on teaching an appropriate functional communicative response (FCR) to access the reinforcer maintaining severe problem behavior (SPB). This procedure involves selecting an appropriate topography for the FCR (e.g., touching a card, exchanging a picture) and using a backward chaining approach. The training will progress from full physical prompts to partial prompts and eventually to independent, unprompted responses, all within a trial-based format.